SM Tolaney

Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

W. M. Sikov, DA Berry, CM Perou et al. · Cancer Research · 2016 · 86 citations

Breast Oncology, Cancer Epidemiology, Overall Survival +14

Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

SM Tolaney, Kevin Kalinsky, Virginia Kaklamani et al. · Cancer Research · 2018 · 71 citations

Breast Oncology, Immunology, Pathology +18

Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

SM Tolaney, Claudio Savulsky, Gursel Aktan et al. · European Journal of Cancer · 2017 · 40 citations

Breast Oncology, Medicine, Immunology +8

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

SM Tolaney, WT Barry, CT Dang et al. · Cancer Research · 2013 · 36 citations

Dfs Events, Breast Oncology, Overall Survival +12

MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

SM Tolaney, Andrew Wardley, Stefania Zambelli et al. · Annals of Oncology · 2019 · 24 citations

Breast Oncology, Oncology, Standard-of-care Chemotherapy +6